Edition:
United Kingdom

Incyte Corp (INCY.OQ)

INCY.OQ on NASDAQ Stock Exchange Global Select Market

85.51USD
8:59pm GMT
Change (% chg)

$-0.52 (-0.60%)
Prev Close
$86.03
Open
$85.60
Day's High
$87.56
Day's Low
$84.58
Volume
492,301
Avg. Vol
583,119
52-wk High
$153.14
52-wk Low
$80.99

Latest Key Developments (Source: Significant Developments)

Incyte Corp - Co, Syros Pharmaceuticals Have Entered Into Target Discovery, Research Collaboration And Option Agreement
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Incyte Corp ::INCYTE CORP - CO, SYROS PHARMACEUTICALS HAVE ENTERED INTO A TARGET DISCOVERY, RESEARCH COLLABORATION AND OPTION AGREEMENT.INCYTE-‍UNDER AGREEMENT, SYROS TO USE ITS GENE CONTROL PLATFORM TO IDENTIFY NOVEL THERAPEUTIC TARGETS WITH FOCUS IN MYELOPROLIFERATIVE NEOPLASMS​.INCYTE - CO TO HAVE EXCLUSIVE WORLDWIDE RIGHTS TO DEVELOP AND COMMERCIALIZE ANY THERAPIES UNDER COLLABORATION THAT MODULATE VALIDATED TARGETS​.INCYTE - UNDER DEAL, CO TO GET OPTIONS TO GET EXCLUSIVE WORLDWIDE RIGHTS TO INTELLECTUAL PROPERTY FROM COLLABORATION FOR UP TO SEVEN VALIDATED TARGETS.INCYTE CORP - ‍ UNDER TERMS , CO TO PAY SYROS $10 MILLION UPFRONT AND PURCHASE A TOTAL OF $10 MILLION IN SYROS COMMON STOCK AT $12.61 PER SHARE​.INCYTE - SHOULD INCYTE EXERCISE ALL OF ITS OPTIONS UNDER DEAL, SYROS COULD GET UP TO $54 MILLION FROM INCYTE IN TARGET SELECTION & OPTION EXERCISE FEES.INCYTE CORP - SYROS COULD ALSO RECEIVE UP TO $50 MILLION IN DEVELOPMENT AND REGULATORY MILESTONES, AS WELL AS UP TO $65 MILLION IN COMMERCIAL MILESTONES.INCYTE CORP - SYROS WOULD ALSO BE ELIGIBLE TO RECEIVE LOW SINGLE-DIGIT ROYALTIES ON SALES OF PRODUCTS RESULTING FROM COLLABORATION.  Full Article

Immunovaccine announces positive clinical data from its collaborative combination immunotherapy trial in advanced ovarian cancer
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Immunovaccine Inc ::IMMUNOVACCINE ANNOUNCES POSITIVE CLINICAL DATA FROM ITS COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL IN ADVANCED OVARIAN CANCER.IMMUNOVACCINE INC - ‍DATA FROM FIRST DOSING COHORT FROM COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL​ SHOW A 70% DISEASE CONTROL RATE DATA.IMMUNOVACCINE - EXPECTS TO PROVIDE CLINICAL UPDATE ON SECOND DOSING COHORT OF DPX-SURVIVAC IN FIRST HALF OF 2018.IMMUNOVACCINE - ‍DATA FROM FIRST DOSING COHORT FROM COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL FOR DPX-SURVIVAC​DEMONSTRATE TOLERABLE SAFETY PROFILE.  Full Article

Incyte initiates clinical trial of Ruxolitinib for treatment of essential thrombocythemia
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Incyte Corp :Incyte announces initiation of pivotal clinical trial of Ruxolitinib (Jakafi®) for the treatment of essential thrombocythemia.Incyte Corp - ‍announced that first patient has been treated in reset pivotal trial evaluating Ruxolitinib​.  Full Article

Incyte says Q3 earnings per share $0.17
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Incyte Corp -:Incyte reports 2017 third-quarter financial results and updates on key clinical programs.Q3 revenue $382 million versus I/B/E/S view $360.2 million.Q3 earnings per share $0.17.Q3 earnings per share view $0.07 -- Thomson Reuters I/B/E/S.Incyte Corp- for the quarter ended September 30, 2017, total revenues were $382 million as compared to $269 million for the same period in 2016.Incyte Corp - co updated FY 2017 financial guidance‍​.Incyte Corp now sees FY 2017 Jakafi net product revenues in a range of $1,125 million to $1,135 million versus prior view of $1,090 million to $1,120 mln‍​.Incyte Corp - reaffirms Iclusig net product revenues FY 2017 guidance.  Full Article

Incyte and AstraZeneca to enter clinical trial collaboration in early lung cancer
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Incyte Corp :Incyte and AstraZeneca to enter clinical trial collaboration in early lung cancer.Incyte - ‍phase 3 trial evaluating Imfinzi and epacadostat in patients with unresectable non-small cell lung cancer is expected to begin in first-half 2018​.  Full Article

Incyte and MacroGenics announce global collaboration and licensing agreement
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Incyte Corp :Incyte and MacroGenics announce global collaboration and licensing agreement for Anti-PD-1 Monoclonal Antibody MGA012.MacroGenics inc - ‍Incyte gains exclusive, worldwide development and commercialization rights to MGA012 in all indications​.MacroGenics Inc - ‍upon closing, Incyte will pay MacroGenics an upfront payment of $150 million​.MacroGenics - ‍co is eligible to receive up to $420 million in potential development, regulatory milestones, up to $330 million in potential commercial milestones​.MacroGenics Inc - ‍MacroGenics retains right to manufacture a portion of both companies' global clinical and commercial supply needs of MGA012​.MacroGenics Inc - ‍MacroGenics intends to utilize its commercial-scale GMP facility, which is expected to be fully operational in 2018​.MacroGenics - ‍if MGA012 approved & commercialized, co will be eligible to get royalties, tiered from 15 percent to 24 percent, on future sales by Incyte​.  Full Article

Concert Pharma Says PTAB denies Incyte petition challenging CTP-543 patent
Thursday, 19 Oct 2017 

Oct 19 (Reuters) - Concert Pharmaceuticals Inc ::Concert Pharma says patent trials and appeal board of u.s. patent and trademark office has denied Incyte's petition to institute IPR​.  Full Article

European Commission approves once-daily olumiant tablets for treatment of rheumatoid arthritis
Monday, 13 Feb 2017 

Incyte Corp : European Commission approves once-daily olumiant tablets for treatment of adults with moderate-to-severe active rheumatoid arthritis . Incyte -as a result of approval of olumiant by European Commission, Incyte becomes eligible to receive a milestone payment of $65 million from Lilly .Incyte Corp - Phase 3 trial for patients with psoriatic arthritis is expected to be initiated in 2017.  Full Article

Incyte reported Q2 EPS $0.18
Tuesday, 9 Aug 2016 

Incyte Corp : Quarter financial results and updates key clinical programs . Q2 earnings per share $0.18 . Q2 earnings per share view $-0.02 -- Thomson Reuters I/B/E/S . Q2 revenue $246 million versus I/B/E/S view $234.5 million .Sees 2016 Jakafi net product revenue $825 mln - $835 million.  Full Article

Agenus Inc starts phase 1/2 clinical trial of anti-GITR agonist antibody
Wednesday, 22 Jun 2016 

Agenus Inc : Expect to initiate additional clinical studies with antibodies and immuno-oncology leads from comprehensive pipeline in next twelve months .Agenus announces commencement of phase 1/2 clinical trial of anti-GITR checkpoint antibody INCAGN1876 in patients with solid tumors.  Full Article

BRIEF-Incyte Corp Q4 Loss Per Share $0.71

* INCYTE REPORTS 2017 FOURTH-QUARTER AND YEAR-END FINANCIAL RESULTS, PROVIDES 2018 FINANCIAL GUIDANCE AND UPDATES ON KEY CLINICAL PROGRAMS